# OnCo record opm-101 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/opm-101/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "opm-101" ;
  schema:name "OPM-101"@en ;
  schema:description "OPM-101 is an experimental oral small-molecule kinase inhibitor from Oncodesign Precision Medicine, in phase 1 trials for advanced melanoma resistant to anti-PD-1."@en ;
  schema:url <https://onco.cc/drugs/opm-101/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.oncodesign.com/our-pipeline/opm-101/>, <https://www.oncodesign.com/our-pipeline/opm-101/>, <https://clinicaltrials.gov/study/NCT07040436>, <https://clinicaltrials.gov/search?intr=OPM-101> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral small-molecule kinase inhibitor (macrocyclic, Nanocyclix platform)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:targets <https://onco.cc/targets/ripk2/> ;
  onco:companies <https://onco.cc/companies/oncodesign-precision-medicine/> ;
  onco:trials <https://onco.cc/trials/nct07040436/> .